Diabecon

THE BEACON OF HOPE FOR DIABETICS

How does it work?

Diabecon promotes the repair/regeneration of β – cells and increases the C-peptide levels.

Diabecon promotes α-glycosidase inhibitory activity and glucose utilization through stimulatory activity.

Diabecon exhibits insulinomimetic activities that reduce high glucose content in the blood. Effective glycemic control is important in preventing micro and macro vascular complications arising from diabetes.

Key ingredients:

Gymnema’s (Meshashringi) principal constituent is gymnemic acid, which has antidiabetic properties. It reduces excessive blood sugar and has a regenerative effect on pancreatic beta cells and is insulinotropic.

Indian Kino Tree’s (Pitasara) principal constituent, epicatechin, has alpha-glucosidase inhibitory properties and regularizes key metabolic enzymes involved in carbohydrate metabolism.

Shilajeet decreases hepatic glucose production and prevents hyperglycemia. Shilajeet has a protective action on b-cells of the pancreas, and promotes unrestricted endogenous insulin action.

Category:

In patients on sulfonylurea therapy:

  • Prevents development of tolerance
  • Reduces the risk of secondary failure

In patients on biguanide therapy:

  • Improves peripheral utilization of glucose without GI adverse events

In patients on insulin therapy:

  • Helps in reducing the dose
  • Insulin secretagogue
  • Antihyperglycemic
  • Alpha-glucosidase inhibitory
  • Prediabetes NIDDM
  • Newly detected type 2 diabetes
  • Type 2 diabetes with micro- and macrovascular complications
  • As an adjuvant in IDDM– Type 1

Monotherapy:

  • 2 tablets twice daily before food in newly detected type 2 diabetes

Adjuvant therapy:

  • 1 tablet twice daily before food as an adjuvant to OHAs or insulin
  • The dosage may be titrated depending on the patient’s response

Diabecon DS:

  • 1 tablet twice daily